Organic compounds

US7807709B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Claus Ehrhardt · Lörrach, DE
• Osamu Irie · Ibaraki, JP
• Edwige Liliane Jeanne Lorthiois · Niffer, FR
• Juergen Klaus Maibaum · Basel, CH
• Nils Ostermann · Binzen, DE
• Holger Sellner · Buchs, CH

Key dates

• Filing date: Mar 21, 2006
• Grant date: Oct 5, 2010
• Expiry date: Aug 5, 2026

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to the use of (3,4-di-, 3,3,4-tri, 3,4,4-tri- or 3,3,4,4-tetra-)substituted pyrrolidine compounds for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; compounds that are part of a subclass of these substituted pyrrolidine compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; new compounds that are part of a subclass of these substituted pyrrolidine compounds; pharmaceutical formulations comprising said substituted pyrrolidine compounds, and/or a method of treatment comprising administering said substituted pyrrolidine compounds, a method for the manufacture especially of said new substituted pyrrolidine compounds, as well as novel intermediates, starting materials and/or partial steps for their synthesis.